Amneal Pharmaceuticals, Inc. AMRX Affordable Medicines — Gross Profit
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GrossProfit.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s affordable medicines — gross profit.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s affordable medicines — gross profit?
- Amneal Pharmaceuticals, Inc. (AMRX) reported affordable medicines — gross profit of $190.79M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s affordable medicines — gross profit changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s affordable medicines — gross profit increased by 10.9% year-over-year, from $172.08M to $190.79M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s affordable medicines — gross profit?
- Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s affordable medicines — gross profit has grown at a 8.5% compound annual growth rate (CAGR), from $536.04M to $683.92M.
- What does affordable medicines — gross profit mean?
- Calculated as net revenue minus the cost of goods sold for the Affordable Medicines segment, representing the core profitability of the product line before operating expenses. It provides insight into the segment's pricing power and manufacturing cost structure.